Price movement over the last 24 hours
Alcon AG vs Avient Corporation — how do they compare? Alcon AG trades at $66.86 (market cap $32.69B), while Avient Corporation trades at $35.5 (market cap $3.49B). The key difference: Alcon AG is far larger — about 9.4× Avient Corporation's market cap, and Avient Corporation pays the higher dividend (2.89%). Which is the better fit depends on your goals.
| ALC | AVNT | |
|---|---|---|
Market Cap | $32.69B | $3.49B |
Sector | Health | Technology |
52-Week High | $92.22 | $43.28 |
52-Week Low | $62.02 | $27.48 |
Enterprise Value | $36.28B | $4.99B |
Dividend Yield | 0.54% | 2.89% |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Avient Corporation (AVNT) trades at $38.89, up 4.23% today, reflecting positive momentum. The stock exhibits a bullish technical outlook with strong analyst support (12 Buy, 8 Hold, 0 Sell). Recent quarterly earnings have consistently beaten estimates, with Q1 2026 EPS of $0.83 surpassing the $0.81 forecast. The company maintains solid fundamentals, including a P/E of 22.58 and net income margin of 4.81%, while recent news highlights innovation in non-PFAS barrier technology and new dielectric thermoplastics.
The outlook for AVNT is positive, driven by earnings outperformance, strategic product launches, and favorable analyst sentiment. Key opportunities include growth in 5G/6G materials and sustainable packaging solutions. Risks involve exposure to economic cycles impacting demand and competitive pressures in the specialty materials sector. Investors should weigh strong fundamentals against market volatility and execution risks.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →Avient Corporation is a global leader in specialized and sustainable material solutions. Formed from the legacy of PolyOne and Clariant’s masterbatch business, it provides highly engineered polymer formulations, color systems, and advanced composites that enhance the performance and sustainability of products in industries like healthcare, defense, and consumer packaging.
Read more on AVNT →